Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1488]
News [2333]
Articles [44]
Editorials [5]
Conferences [171]
elearning [0]
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan
Long-term viral hepatitis control and changing patterns of liver cancer mortality in Japan
NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia
NCCN highlights collaborations to improve global cancer outcomes during meetings in North America and Asia
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer
Europe now runs just one in five of the world’s cancer trials
Europe now runs just one in five of the world’s cancer trials
International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases
International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma
New spatiotemporal precision management framework proposed for gastric and colorectal cancers
New spatiotemporal precision management framework proposed for gastric and colorectal cancers
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway
Regulator-mandated study finds no link between semaglutide use and pancreatic cancer using nationwide registry...
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation